NEW YORK (GenomeWeb) – Merck and NanoString Technologies today announced a research collaboration to develop an assay to evaluate the potential benefits to a patient treated with Merck's anti-PD-1 therapy Keytruda (pembrolizumab).

The assay will be based on immune-related gene expression signatures and will be developed using NanoString's nCounter analysis system to optimize gene expression signatures as part of the clinical development of Keytruda.

Keytruda is a monoclonal antibody that blocks interaction between PD-1 and its ligands.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

Five researchers are to share this year's Albany Medical Center Prize for their work on the CRISPR/Cas9 gene-editing tool, the AP reports.

Stat News reports on how white supremacists cope with surprising genetic ancestry testing results.

In Genome Research this week: sex-biased gene expression evolution in malaria mosquitos, method to find ancient selective sweeps, and more.

Iceland has nearly eliminated Down syndrome from its population, CBS News reports.